Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution
Khurum Hayat Khana b, Nicola Valeria, Charles Dearmana, Sheela Raoa, David J. Watkinsa, Naureen Starlinga, Ian Chaua, David Cunninghama c✉
- aGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK
- bGastrointestinal Unit, University College London Hospitals, 250 Euston Road London, NW1 2AF, UK
- cGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK. Electronic address: david.cunningham@rmh.nhs.uk
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Despite significant progress in management of metastatic colorectal cancer (mCRC) pertaining to better screening procedures and amelioration of the therapeutic armamentarium with targeted therapies, prognosis remains poor. Targeting epidermal growth factor receptor (EGFR) has been of particular interest owing to favourable efficacy benefits demonstrated by monoclonal antibodies (cetuximab and panitumumab) in various clinical settings and development of predictive biomarkers informing treatment decisions respectively. In spite of optimal patient selection based on RAS mutation status, primary and secondary resistance to monoclonal antibodies is higher than desired. Further research into predictive biomarkers is therefore essential, but has, to date, been conducted with considerable limitations. Whilst molecular heterogeneity has been demonstrated by several studies in mCRC, for incomprehensible reasons, multiple resistant genetic alterations that emerge under the selective pressure of EGFR-targeted therapies are somehow able to influence the biological and clinical behaviour of cancer cells, despite being detectable at extremely low frequencies. Intriguingly, these subclonal events largely seem to converge on RAS/RAF/MAPK pathway in patients treated with EGFR-targeted monoclonal antibodies. This review describes the clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine.
TL;DRThe clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine are described. (Semantic Scholar)